Clinical Trials for Small Cell Lung Cancer

A Phase 1, Open-Label, Dose Escalation and Expansion Study of Mavrostobart (PT199) Administered Alone in Adult Patients with Advanced Solid TuMORs, in CombiNation with a Checkpoint INhibitor TreatinG Wild-type Non-Small Cell Lung Cancer, or in Combination with ChemoTherapy for Metastatic or Advanced PAncreatic Ductal AdenocaRcinoma (MORNINGSTAR)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, including NSCLC without actionable alterations and pancreatic ductal adenocarcinoma, receive investigational mavrostobart alone or with a PD-1 inhibitor and/or cohort-specific chemotherapy. Mavrostobart is an anti-CD73 antibody designed to reduce adenosine-mediated immune suppression.

ClinicalTrials.gov ID: NCT05431270

A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent, unresectable advanced or metastatic cancers harboring eligible KRAS non-G12C, BRAF, CRAF, or NRAS alterations receive oral BDTX-4933, an investigational RAF inhibitor designed to block signaling through active RAF dimers. Dose expansion is limited to patients with radiographically progressing KRAS non-G12C–mutant NSCLC.

ClinicalTrials.gov ID: NCT05786924

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors refractory to or intolerant of standard therapy receive oral JAB-2485 monotherapy, an investigational Aurora kinase A inhibitor. Expansion cohorts focus on ER-positive breast cancer, triple-negative breast cancer, ARID1A-mutant solid tumors, and small-cell lung cancer.

ClinicalTrials.gov ID: NCT05490472

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent or metastatic GRPR-expressing mCRPC, HR-positive/HER2-negative breast cancer, colorectal cancer, cervical cancer, cutaneous melanoma, or NSCLC are eligible if they have a lesion with uptake greater than liver on GRPR imaging; recurrent disease must have progressed after at least two systemic therapies. Participants receive up to four cycles of investigational ²¹²Pb-DOTAM-GRPR1, a GRPR-targeted radiopharmaceutical that delivers DNA-damaging alpha radiation.

ClinicalTrials.gov ID: NCT05283330

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable advanced or metastatic small-cell lung cancer, pulmonary large-cell neuroendocrine carcinoma, or extrapulmonary neuroendocrine carcinoma are eligible according to cohort-specific prior treatment criteria. Peluntamig, an investigational DLL3/CD47-targeting bispecific antibody, is given alone or with carboplatin/etoposide, paclitaxel, atezolizumab, or carboplatin/etoposide plus atezolizumab.

ClinicalTrials.gov ID: NCT05652686

Phase 1 Trial With GD2-SADA:177Lu-DOTA Drug Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Patients with recurrent or refractory metastatic GD2-expressing solid tumors, including small-cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma, receive GD2-SADA followed by ¹⁷⁷Lu-DOTA. GD2-SADA binds tumor-associated GD2 and captures the radioactive payload to concentrate radiation in tumors.

ClinicalTrials.gov ID: NCT05130255

An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced solid tumors lacking standard treatment options may receive intravenous ADU-1805 alone or with pembrolizumab; combination expansion cohorts enroll selected patients with microsatellite-stable colorectal or endometrial cancer, renal cell carcinoma, or non-small cell lung cancer. ADU-1805 is an investigational anti-SIRPα antibody designed to block the SIRPα–CD47 signal and promote macrophage engulfment of tumor cells.

ClinicalTrials.gov ID: NCT05856981

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

Restricted enrollment

The trial has restricted enrollment. For instance, you may only be eligible to participate if you were enrolled in a specific prior trial.

TrialFetch AI summary: This trial enrolls patients with BRAF V600E/K mutant cancers who previously received and benefited from dabrafenib (a BRAF inhibitor), trametinib (a MEK inhibitor), or their combination in Novartis or GSK-sponsored studies, and who lack access to commercial therapy. Patients continue their prior targeted regimen to assess long-term safety and tolerability.

ClinicalTrials.gov ID: NCT03340506